#1 Clinical Trials Search in Europe

Feladilimab

This article examines the use of feladilimab, an innovative immunotherapy drug, in various clinical trials for cancer treatment. Feladilimab is being studied alone and in combination with other therapies for different types of cancer, including non-small cell lung cancer, head and neck cancer, and multiple myeloma. The trials aim to evaluate the safety, efficacy, and potential benefits of feladilimab in improving patient outcomes.

Table of Contents

What is Feladilimab?

Feladilimab is an experimental drug being developed for the treatment of various types of cancer. It is also known by several other names, including GSK3359609 and EOS884448[4]. Feladilimab belongs to a class of drugs called immunotherapy, which work by helping the body’s immune system fight cancer cells[2].

This medication is not yet approved for general use and is currently being studied in clinical trials to determine its safety and effectiveness in treating different types of cancer[1].

How Does Feladilimab Work?

Feladilimab is a type of drug called a monoclonal antibody. Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful pathogens like cancer cells. Specifically, feladilimab is an anti-ICOS agonist antibody[5].

ICOS stands for Inducible T cell Co-Stimulator. It’s a protein found on the surface of certain immune cells called T cells. By targeting and activating ICOS, feladilimab aims to boost the immune system’s ability to recognize and attack cancer cells[6].

What Conditions Does Feladilimab Treat?

Feladilimab is being studied for the treatment of several types of cancer, including:

  • Non-small cell lung cancer (NSCLC): This is the most common type of lung cancer[1].
  • Head and neck squamous cell carcinoma (HNSCC): This is a type of cancer that affects the mouth, nose, and throat[2].
  • Multiple myeloma: A cancer of plasma cells, which are a type of white blood cell[7].
  • Other advanced solid tumors: This refers to various types of cancers that form solid masses[3].

Clinical Trials and Research

Feladilimab is being studied in several clinical trials to evaluate its effectiveness and safety. These trials are testing feladilimab both as a single treatment and in combination with other cancer drugs. Some key points about the ongoing research include:

  • Combination with other immunotherapy drugs: Feladilimab is being tested alongside drugs like pembrolizumab and ipilimumab, which are also immunotherapies[2][3].
  • Combination with chemotherapy: Some trials are exploring how feladilimab works when given with standard chemotherapy drugs[6].
  • Comparison to standard treatments: Researchers are comparing feladilimab to current standard-of-care treatments to see if it offers any advantages[1].
  • Different dosing schedules: Various doses and treatment schedules are being tested to find the most effective and safe way to administer the drug[5].

Potential Side Effects

As with all medications, feladilimab can cause side effects. In clinical trials, researchers are carefully monitoring patients for any adverse reactions. Some potential side effects that have been observed include:

  • Immune-related adverse events: Because feladilimab works by stimulating the immune system, it can sometimes cause the immune system to attack healthy tissues. This can lead to inflammation in various parts of the body[2].
  • Infusion-related reactions: Some patients may experience reactions during or shortly after receiving the drug through an IV[1].
  • Fatigue: Feeling very tired is a common side effect of many cancer treatments, including immunotherapies[3].
  • Changes in blood tests: Feladilimab may affect various blood cell counts and other laboratory test results[5].

It’s important to note that not all patients will experience these side effects, and the full range of potential side effects is still being studied in clinical trials.

Future Prospects

Feladilimab is still in the early stages of development, but researchers are hopeful about its potential. If the ongoing clinical trials show positive results, feladilimab could become a valuable new option for treating various types of cancer[4].

Some areas of particular interest for future research include:

  • Identifying which patients are most likely to benefit from feladilimab treatment[2].
  • Exploring additional combination treatments to enhance the effectiveness of feladilimab[7].
  • Investigating feladilimab’s potential in treating other types of cancer not currently being studied[5].

As research continues, we may learn more about how feladilimab can be used to help patients with various forms of cancer. Patients interested in learning more about feladilimab should speak with their healthcare provider about the latest developments and potential clinical trial opportunities.

Aspect Details
Drug Name Feladilimab (GSK3359609)
Drug Type Humanized anti-ICOS agonist immunoglobulin G4 (IgG4) monoclonal antibody
Administration Intravenous (IV) infusion, typically every 3 weeks
Cancer Types Studied Non-small cell lung cancer (NSCLC), Head and neck squamous cell carcinoma (HNSCC), Multiple myeloma
Combination Therapies Pembrolizumab, Ipilimumab, Chemotherapy regimens, Belantamab mafodotin
Primary Outcomes Safety, tolerability, adverse events, dose-limiting toxicities
Secondary Outcomes Overall survival, progression-free survival, objective response rate, duration of response
Study Phases Phase I, II, and III trials
Key Measurements Pharmacokinetics, pharmacodynamics, anti-drug antibodies, receptor occupancy

FAQ

  • What is feladilimab? Feladilimab is an immunotherapy drug that acts as an agonist of the inducible T cell co-stimulatory receptor (ICOS). It is designed to stimulate the immune system to fight cancer cells.
  • What types of cancer is feladilimab being studied for? Feladilimab is being investigated in clinical trials for various cancer types, including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and multiple myeloma.
  • How is feladilimab administered? Feladilimab is typically administered as an intravenous (IV) infusion, usually once every three weeks or as determined by the specific trial protocol.
  • What are some common combinations being tested with feladilimab? Feladilimab is being studied in combination with other cancer treatments such as pembrolizumab (an anti-PD-1 drug), ipilimumab (an anti-CTLA-4 drug), chemotherapy regimens, and other novel agents like belantamab mafodotin for multiple myeloma.
  • What are the main goals of these clinical trials? The primary goals of these trials are to assess the safety and tolerability of feladilimab, determine appropriate dosing, evaluate its efficacy in terms of tumor response and survival outcomes, and understand its pharmacokinetics and pharmacodynamics when used alone or in combination with other treatments.

Ongoing Clinical Trials on Feladilimab

  • Study of Belantamab Mafodotin Alone and with Drug Combination for Patients with Relapsed/Refractory Multiple Myeloma

    Not recruiting

    1 1 1
    Investigated drugs:
    France Norway Poland Sweden

Glossary

  • Feladilimab: A humanized anti-ICOS agonist immunoglobulin G4 (IgG4) monoclonal antibody designed to stimulate the immune system's response against cancer cells.
  • ICOS: Inducible T cell co-stimulatory receptor, a protein on T cells that plays a role in immune system activation.
  • Immunotherapy: A type of cancer treatment that helps the body's immune system fight cancer cells.
  • Non-small cell lung cancer (NSCLC): A type of lung cancer that is the most common form of the disease, accounting for about 80-85% of all lung cancers.
  • Head and neck squamous cell carcinoma (HNSCC): A type of cancer that begins in the squamous cells that line the moist surfaces inside the head and neck.
  • Multiple myeloma: A cancer of plasma cells, a type of white blood cell that normally produces antibodies to help fight infections.
  • Pembrolizumab: An immunotherapy drug that targets the PD-1 receptor on T cells to help the immune system fight cancer.
  • Ipilimumab: An immunotherapy drug that targets CTLA-4, a protein that helps regulate the immune system's response to cancer cells.
  • Intravenous (IV) infusion: A method of delivering medications directly into the bloodstream through a vein.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Pharmacodynamics: The study of the biochemical and physiological effects of drugs on the body, including their mechanisms of action.
  • Overall survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Objective response rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Adverse events (AEs): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Serious adverse events (SAEs): Adverse events that result in death, are life-threatening, require hospitalization, cause persistent or significant disability, or are otherwise medically significant.

References

  1. https://clinicaltrials.gov/study/NCT05553808
  2. https://clinicaltrials.gov/study/NCT04128696
  3. https://clinicaltrials.gov/study/NCT03693612
  4. https://clinicaltrials.gov/study/NCT03739710
  5. https://clinicaltrials.gov/study/NCT02723955
  6. https://clinicaltrials.gov/study/NCT04428333
  7. https://clinicaltrials.gov/study/NCT04126200